Skip to content

Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates

Liberal versus restrictive platelet transfusion for treatment of hemodynamically significant patent ductus arteriosus in thrombocytopenic preterm neonates- A randomized open label, controlled trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007660
Enrollment
44
Registered
2017-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Neonates with gestational age less than 35 weeks with hemodynamically significant PDA

Interventions

Intervention1: Platelet transfusion: We will transfuse platelet concentrates to maintain platelet count above 1, 00,000 per micro liter until one of the following endpoints is met, whichever is applic

Sponsors

Postgraduate Institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gestational age less than 35 weeks 2) PDA detected for the first time at less than 14 days of postnatal age 3) Clinically and/or echocardiographically hemodynamically significant PDA Note: ELBW neonates will be screened in first 48 hours as per unit policy; the rest will undergo echocardiography only when there are clinical signs of PDA. 4) Platelet count within 24 hours prior to inclusion is less than 100,000 per microliter. Note: If a platelet count is already available within 24 hours prior to inclusion it will be accepted as a valid platelet count. If not, an urgent absolute platelet count will be performed.

Exclusion criteria

Exclusion criteria: Echocardiographically proven structural congenital heart disease. 2) Major life-threatening malformation 3) Received platelet concentrate between the last available platelet count and the point of randomisation

Design outcomes

Primary

MeasureTime frame
The primary outcome variable will be time to closure of PDA post randomizationTimepoint: The primary outcome variable will be time to closure of PDA post randomization within a 5 day period

Secondary

MeasureTime frame
Clinical bleed of any kind within 120 hours after randomizationTimepoint: 120 hours after randomization;Cumulative volume of platelet concentrate received within 120 hours after randomizationTimepoint: 120 hours after randomization;Duration of hospital stayTimepoint: Duration of hospital stay;Mortality anytime during hospital stayTimepoint: anytime during hospital stay;Mortality within 120 hours after randomizationTimepoint: 120 hours after randomization;New onset IVH of any grade within 120 hours after randomizationTimepoint: 120 hours after randomization;New onset IVH of grade 3,4 within 120 hours after randomizationTimepoint: 120 hours after randomization;Proportion in whom PDA is echocardiographically hemodynamically significant at 120 hours after randomizationTimepoint: 120 hours after randomization;Proportion in whom PDA is open at 120 hours after randomizationTimepoint: 120 hours after randomization;Reopening rate of PDA that had initially closed within 120 hours of randomizationTimepoint: within 120 hours of randomization

Countries

India

Contacts

Public ContactSOURABH DUTTA

Post Graduate Institute of Medical Education and Research, Chandigarh

sourabhdutta1@gmail.com8283831967

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026